Empiric IV Antibiotic Recommendations for Post‑Surgical Abdominal Infections

Initial Empiric Therapy

• Piperacillin‑tazobactam 3.375 g IV every 6 h (or 4.5 g IV every 6 h for severe infections) provides optimal broad‑spectrum coverage against the typical polymicrobial flora of postoperative abdominal infections. 1, 2

Risk‑Based Antibiotic Selection

Non‑Critically Ill Patients (no sepsis or septic shock)

• First‑line therapy is piperacillin‑tazobactam 4.5 g IV every 6 h, which covers gram‑negative aerobes, anaerobes, and ampicillin‑susceptible enterococci. 2

Critically Ill or High‑Risk for Multidrug‑Resistant Organisms (MDRO)

• Carbapenem monotherapy (meropenem 1 g IV q8 h, imipenem‑cilastatin 1 g IV q8 h, or doripenem 500 mg IV q8 h) is recommended. 1, 2
• Add vancomycin 15–20 mg/kg IV q8–12 h (loading dose 25–30 mg/kg) when MRSA risk factors are present (known colonization, prior treatment failure, or significant recent antibiotic exposure). 1, 2

Carbapenem‑Sparing Regimens

• Piperacillin‑tazobactam 4.5 g IV q6 h + tigecycline (100 mg loading, then 50 mg IV q12 h). 2
• Ceftolozane‑tazobactam 1.5 g IV q8 h + metronidazole 500 mg IV q6 h. 2

Enterococcal Coverage

• Routine enterococcal coverage is not required for community‑acquired postoperative infections. 1
• Add ampicillin 2 g IV q6 h for immunocompromised patients, recent antibiotic exposure, or when the regimen does not already include agents with intrinsic enterococcal activity (e.g., piperacillin‑tazobactam or imipenem‑cilastatin). 1, 2
• For high‑risk patients with known VRE colonization, use linezolid 600 mg IV q12 h or daptomycin 6 mg/kg IV q24 h. 1, 2

MRSA Coverage

• Vancomycin is the recommended agent for suspected or proven MRSA in postoperative intra‑abdominal infections. 1
• Empiric MRSA coverage should be instituted when any of the following are present: known MRSA colonization, prior treatment failure, or significant recent antibiotic exposure. 1

Candida Coverage

• For patients at high risk of invasive candidiasis (e.g., recurrent perforations, anastomotic leaks, immunosuppression), echinocandins are preferred (caspofungin, micafungin, or anidulafungin). 2
• Fluconazole (800 mg loading, then 400 mg IV q24 h) is an alternative for less critically ill patients. 2

Adjunctive Agents

Aminoglycoside Dosing (when used in combination)

• Gentamicin or tobramycin: 5–7 mg/kg IV q24 h (based on adjusted body weight).
• Amikacin: 15–20 mg/kg IV q24 h.
• Therapeutic drug monitoring is required to individualize dosing. 1

Severe β‑Lactam Allergy Alternatives

• Ciprofloxacin 400 mg IV q12 h + metronidazole 500 mg IV q8–12 h. 1
• Alternatively, an aminoglycoside‑based regimen combined with metronidazole. 1

Microbiologic Guidance, De‑escalation, and Duration

• Obtain intra‑operative cultures from all postoperative infections to direct subsequent therapy. 1
• De‑escalate antimicrobial regimens based on culture results, especially in lower‑risk patients who show satisfactory clinical response. 1
• Blood cultures should be drawn when the patient appears toxic or immunocompromised, as bacteremia may affect therapy duration. 3
• Pathogen‑directed therapy should be guided by organisms recovered from blood cultures or from drainage samples with moderate‑to‑heavy growth. 1

Common Pitfalls to Avoid

• Do not use ertapenem for healthcare‑associated postoperative infections because it lacks Pseudomonas coverage; reserve it for community‑acquired infections only. 1, 2
• Avoid fluoroquinolones as monotherapy due to rising E. coli resistance; always review local susceptibility patterns before employing ciprofloxacin or levofloxacin‑based regimens. 3